Company: AZN
Filing Date: 2025-04-29
Form Type: 6-K
Source: 0001654954-25-004737
Chunk: 9

Company: ASTRAZENECA PLC
Filing Date: 2025-04-29
Form: 6-K
Chunk 9
---
 Phase III trial showed that       
 camizestrant in combination with a CDK4/6 inhibitor demonstrated a 
 highly statistically significant and clinically meaningful         
 improvement in the primary endpoint of PFS. The trial evaluated    
 switching to the camizestrant combination versus continuing        
 standard-of-care treatment with akin aromatase inhibitor in        
 combination with a CDK4/6 inhibitor in the 1st-line treatment of   
 patients with HR-positive, HER2-negative advanced breast cancer    
 whose tumours have an emergentESR1mutation.                        |

BioPharmaceuticals - CVRM

AZD0780

| Phase II presentation 
 ACC                   | PURSUIT    
 March 2025 | ∗At 12 weeks, AZD0780 30mg taken once-daily                         
 (when added to the standard-of-care statin therapy and administered 
 without any fasting or food restrictions) led to a 50.7% reduction  
 in LDL-C. Similar efficacy was observed regardless of whether trial 
 participants received moderate- or high-intensity statin doses at   
 baseline.                                                           |

Wainzua

| Approval 
 EU       | NEURO-TTRansform 
 March 2025       | ∗For the treatment of hereditary                                  
 transthyretin-mediated amyloidosis in adult patients with stage 1 
 or stage 2 polyneuropathy, commonly referred to as hATTR-PN or    
 ATTRv-PN.                                                         |

BioPharmaceuticals - R&I

Tezspire

| Phase III presentation 
 AAAAI                  | WAYPOINT   
 March 2025 | ∗Treatment withTezspiresignificantly reduced nasal polyp severity  
 measured by the co-primary endpoints; Nasal Polyp Score by -2.065  
 (95% CI: -2.389, -1.742; p<0.0001) and nasal congestion            
 (measured by participant-reported Nasal Congestion Score)by -1.028 
 (95% CI: -1.201, -0.855; p<0.0001) at week 52 compared to          
 placebo.Tezspiresignificantly                                      
 reduced the need for subsequent nasal polyp surgery by 98%         
 (p<0.0001) and the need for systemic corticosteroid treatment by   
 88% (p<0.0001) compared to placebo.                                |

Rare Disease

Ultomiris

| Phase III readout |